A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

New treatments are required to enhance current therapies for lung cancer. Mesothelin is a surface protein overexpressed in non-small cell lung cancer (NSCLC) that shows promise as an immunotherapeutic target in phase I clinical trials. However, the immunosuppressive environment in NSCLC may limit ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, Philippa R., Vallera, Daniel A., Ettestad, Brianna, Hallstrom, Caroline, Kodal, Behiye, Todhunter, Deborah A., Bendzick, Laura, Hinderlie, Peter, Walker, Joshua T., Pulkrabek, Brittany, Pastan, Ira, Kratzke, Robert A., Fujioka, Naomi, Miller, Jeffrey S., Felices, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992642/
https://www.ncbi.nlm.nih.gov/pubmed/36911670
http://dx.doi.org/10.3389/fimmu.2023.1060905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992642/
https://www.ncbi.nlm.nih.gov/pubmed/36911670
http://dx.doi.org/10.3389/fimmu.2023.1060905

Ejemplares similares